Cargando…

Randomized trial of intravenous immunoglobulin maintenance treatment regimens in chronic inflammatory demyelinating polyradiculoneuropathy

BACKGROUND AND PURPOSE: High peak serum immunoglobulin G (IgG) levels may not be needed for maintenance intravenous immunoglobulin (IVIg) treatment in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and such high levels may cause side effects. More frequent lower dosing may lead to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kuitwaard, K., Brusse, E., Jacobs, B. C., Vrancken, A. F. J. E., Eftimov, F., Notermans, N. C., van der Kooi, A. J., Fokkink, W. ‐J. R., Nieboer, D., Lingsma, H. F., Merkies, I. S. J., van Doorn, P. A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Neuropathies
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7820989/ https://www.ncbi.nlm.nih.gov/pubmed/32876962 http://dx.doi.org/10.1111/ene.14501

Ejemplares similares

Genetic biomarkers for intravenous immunoglobulin response in chronic inflammatory demyelinating polyradiculoneuropathy
por: Kuitwaard, Krista, et al.
Publicado: (2021)

Misdiagnosis and diagnostic pitfalls of chronic inflammatory demyelinating polyradiculoneuropathy
por: Broers, Merel C., et al.
Publicado: (2021)

Withdrawal of intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy
por: Adrichem, Max E., et al.
Publicado: (2022)

Association of plasma neurofilament light chain with disease activity in chronic inflammatory demyelinating polyradiculoneuropathy
por: Kapoor, Mahima, et al.
Publicado: (2022)

A diagnostic score for anti‐myelin‐associated‐glycoprotein neuropathy or chronic inflammatory demyelinating polyradiculoneuropathy in patients with anti‐myelin‐associated‐glycoprotein antibody
por: Doneddu, Pietro E., et al.
Publicado: (2022)

Diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy in clinical practice: A survey among Dutch neurologists
por: Broers, Merel C., et al.
Publicado: (2020)

Quantitative magnetic resonance imaging of the brachial plexus shows specific changes in nerve architecture in chronic inflammatory demyelinating polyneuropathy, multifocal motor neuropathy and motor neuron disease
por: van Rosmalen, Marieke H. J., et al.
Publicado: (2021)

Dolichoarteriopathies of the extracranial internal carotid artery: The Plaque At RISK study
por: Dilba, Kristine, et al.
Publicado: (2021)

Genetic evidence for the most common risk factors for chronic axonal polyneuropathy in the general population
por: Taams, Noor E., et al.
Publicado: (2022)

Cardiovascular health and chronic axonal polyneuropathy: A population‐based study
por: Taams, Noor E., et al.
Publicado: (2021)

Acute flaccid myelitis and Guillain–Barré syndrome in children: A comparative study with evaluation of diagnostic criteria
por: Helfferich, Jelte, et al.
Publicado: (2021)

Guillain‐Barré syndrome in a patient with antibodies against SARS‐COV‐2
por: Helbok, R., et al.
Publicado: (2020)

Early data on long‐term efficacy and safety of inotersen in patients with hereditary transthyretin amyloidosis: a 2‐year update from the open‐label extension of the NEURO‐TTR trial
por: Brannagan, T. H., et al.
Publicado: (2020)

Epidemiology of chronic inflammatory demyelinating polyradiculoneuropathy in The Netherlands
por: Broers, Merel C., et al.
Publicado: (2022)

Corneal nerve loss is related to the severity of painful diabetic neuropathy
por: Kalteniece, Alise, et al.
Publicado: (2021)

Validation of motor and functional scales for the evaluation of adult patients with 5q spinal muscular atrophy
por: Vázquez‐Costa, Juan F., et al.
Publicado: (2022)

Guillain-Barré syndrome and chronic inflammatory demyelinating polyradiculoneuropathy after alemtuzumab therapy in kidney transplant recipients
por: van der Zwan, Marieke, et al.
Publicado: (2020)

Pregnancy outcome in Charcot–Marie–Tooth disease: results of the CMT‐NET cohort study in Germany
por: Rudnik‐Schöneborn, S., et al.
Publicado: (2020)

Cerebrospinal fluid protein in Guillain–Barré syndrome: Need for age‐dependent interpretation
por: Hegen, Harald, et al.
Publicado: (2020)

Contribution of sleep disturbances to fatigue in multiple sclerosis: a prospective study using clinical and polysomnographic parameters
por: Riccitelli, Gianna C., et al.
Publicado: (2021)

Very early and early neurophysiological abnormalities in Guillain–Barré syndrome: A 4‐year retrospective study
por: Rasera, Andrea, et al.
Publicado: (2021)

Neurofilament light chain and total tau in the differential diagnosis and prognostic evaluation of acute and chronic inflammatory polyneuropathies
por: Kmezic, Ivan, et al.
Publicado: (2022)

Real‐life experience with inotersen in hereditary transthyretin amyloidosis with late‐onset phenotype: Data from an early‐access program in Italy
por: Luigetti, Marco, et al.
Publicado: (2022)

Guillain–Barré syndrome following influenza vaccination: A 15‐year nationwide population‐based case–control study
por: Levison, Lotte Sahin, et al.
Publicado: (2022)

Ictal apnea: A prospective monocentric study in patients with epilepsy
por: Micalizzi, Elisa, et al.
Publicado: (2022)

Frequency, entity and determinants of fatigue in Charcot–Marie–Tooth disease
por: Bellofatto, Marta, et al.
Publicado: (2022)

Electroencephalography functional connectivity—A biomarker for painful polyneuropathy
por: Topaz, Leah Shafran, et al.
Publicado: (2022)

Mutations in MYO9B are associated with Charcot–Marie–Tooth disease type 2 neuropathies and isolated optic atrophy
por: Cipriani, Silvia, et al.
Publicado: (2022)

Hindsight for ultrasound imaging/measurement of the tibial nerve (answer)
por: Dhanapalaratnam, Roshan, et al.
Publicado: (2022)

Primary Sjögren syndrome‐related peripheral neuropathy: A systematic review and meta‐analysis
por: Liampas, Andreas, et al.
Publicado: (2022)

Diagnostic challenges in chronic inflammatory demyelinating polyradiculoneuropathy
por: Eftimov, Filip, et al.
Publicado: (2020)

A randomised, multi‐centre phase III study of 3 different doses of intravenous immunoglobulin 10% in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ProCID trial): Study design and protocol
por: Cornblath, David R., et al.
Publicado: (2018)

Alternatives to intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyradiculoneuropathy
por: Castle, Dan, et al.
Publicado: (2019)

Intravenous immunoglobulin and intravenous methylprednisolone as optimal induction treatment in chronic inflammatory demyelinating polyradiculoneuropathy: protocol of an international, randomised, double-blind, placebo-controlled trial (OPTIC)
por: Bus, S. R. M., et al.
Publicado: (2021)

Risk of Neuropathy with Celiac Disease
por: Millichap, J. Gordon
Publicado: (2015)

Peptides From the Variable Domain of Immunoglobulin G as Biomarkers in Chronic Inflammatory Demyelinating Polyradiculoneuropathy
por: Godelaine, Joris, et al.
Publicado: (2023)

Medical treatment of SUNCT and SUNA: a prospective open-label study including single-arm meta-analysis
por: Lambru, Giorgio, et al.
Publicado: (2021)

Chronic inflammatory demyelinating polyradiculoneuropathy: from pathology to phenotype
por: Mathey, Emily K, et al.
Publicado: (2015)

Intravenous immunoglobulin for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review and meta-analysis
por: Gaebel, Kathryn, et al.
Publicado: (2010)

Parameters Associated with the Required Drug Dose of Intravenous Immunoglobulin in Stable Chronic Inflammatory Demyelinating Polyradiculoneuropathy
por: Feyen, Ludger, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_k1k80gd2l9g1hsul9vdlp4v0m9